Aims-To define the immunopathological profile of transfusion associated graft versus host disease (TA-GvHD) to elucidate its pathophysiology and to determine if any features are of diagnostic value. Methods-Nine patients (age range 14-61 years) who developed histologically confirmed TA-GvHD between 1989 and 1992 were studied. Immunohistochemical analysis of frozen and formalin fixed skin biopsy tissue was performed. Sections were stained with antibodies to CD3, CD8, CD4 and HLA-DR, using a routine streptavidin-biotin technique with standard diaminobenzidine development.
Graft versus host disease (GvHD) is most commonly seen after allogeneic bone marrow transplantation (BMT).' Transfusion associated GvHD (TA-GvHD) following transfusion of non-irradiated blood products in patients with naturally occurring or acquired immune deficiency or suppression is also a well recognised phenomenon.2' With the increasing intensity of treatment for malignancies in both children and adults, TAGvHD is emerging as an increasingly serious problem.
TA-GvHD has a similar clinical presentation to BMT related GvHD-a diffuse erythematous maculopapular rash affecting predominantly proximal areas, typically ensuing six to 10 days after transfusion. However, it has a different clinical course, with a higher mortality and a more rapid and more fulminant course. '4 In contrast to BMT related GvHD, in which marrow aplasia is less pronounced because the marrow is donor derived, TA-GvHD is associated with profound pancytopenia and striking marrow hypocellularity.5 6 In the liver TA-GvHD causes diffuse parenchymal injury,7 in contrast to the isolated biliary epithelial changes associated with the hepatic disease associated with BMT related GvHD. Irradiation of blood products has been shown to abrogate TAGvHD, and its use in the management of immunosuppressed patients is recommended,8 but the dose of radiation required to prevent GvHD while maintaining the viability of the blood product remains contentious. 9 Furthermore, cases of TA-GvHD have been described despite use of irradiated products.'0
The prognosis of TA-GvHD is currently poor. However, treatment at an early stage may be associated with a better prognosis. Early studied (age range 14-61 years). All patients were receiving intensive chemotherapy for primary malignant disease. Each patient's haemoglobin and white cell, neutrophil, lymphocyte, monocyte and platelet count were recorded at the time of the transfusion and at the onset of rash, to assess myelosuppression. Serum concentrations of bilirubin, alkaline phosphatase, and alanine-amino transferase (ALT) were also recorded at the onset of rash, to assess evidence of GvHD induced hepatic dysfunction. At the time of transfusion, seven of the nine patients were lymphopenic, eight were neutropenic, and all nine were thrombocytopenic. Eight patients had a platelet count of less than 50 x 109/1. At the onset of rash, six patients were lymphopenic, seven were neutropenic, and nine were thrombocytopenic. Six had a platelet count of less than 50 x 109/1. Five patients had biochemical evidence of hepatic GvHD, with disordered liver function tests.
The patient details are summarised in tables 1-4.
CASE REPORTS
Case 1 A 61 year old man with chronic lymphocytic leukaemia developed a diffuse erythematous maculopapular rash on the trunk, abdomen, and palms, which was clinically consistent with GvHD, 10 days after transfusion of nonirradiated blood products for pancytopenia secondary to fludarabine treatment. A skin biopsy specimen from the abdomen was consistent with severe GvHD (Lerner grade III).14 He responded poorly to high dose intravenous methylprednisolone and died of GvHD related liver failure five days later.
Case 2
A 53 year old man with non-Hodgkin's lymphoma received non-irradiated blood products for pancytopenia secondary to daunorubicin, cyclophosphamide, and vincristine treatment. He developed jaundice and an extensive dusky erythematous macular rash on the trunk, arms, and shoulders seven days after his last transfusion, one month after starting chemotherapy. A skin biopsy specimen from the shoulder was consistent with moderately severe GvHD (grade II). He was treated with intravenous methylprednisolone but responded poorly and died of GvHD induced liver failure eight days later. Case 3 A 47 year old man with chronic lymphocytic leukaemia developed diarrhoea and a severe diffuse erythematous rash on his back, trunk, and palms 10 days after a transfusion of nonirradiated blood products for pancytopenia secondary to fludarabine treatment. A skin biopsy specimen from the trunk was consistent with moderately severe GvHD (grade II). He was treated with high dose intravenous methylprednisolone, to which he initially responsed, but he deteriorated and died 10 days later of GvHD induced liver failure. Case 
4
A 17 year old girl with a relapsed primitive neuroectodermal tumour (Ewing's sarcoma) of the upper humerus developed an extensive macular rash on the trunk, back, and abdomen six days after transfusion of 3 units of non-irradiated blood products for pancytopenia secondary to second line chemotherapy (ifosfamide, etoposide, and cyclophosphamide). A skin biopsy specimen from the trunk was consistent with moderately severe GvHD (grade II). She responded poorly to high dose intraveous methylprednisolone and died of liver failure five days later. (fig 1) . In four of the patients (Nos 1,2,4,5) keratinocyte expression of HLA-DR was densely and diffusely positive throughout the epidermis. In the other five cases keratinocyte expression of HLA-DR was more focal.
Infiltration of the dermis and epidermis by T cells was noted in all the biopsy specimens, as determined by inflammatory cell expression of either leu 4 (cases 2,5,6,7), or CD3 (cases 1, 3, 4, 8, 9) . In all nine cases CD4 + T cells were the predominant subset. In cases 2,5,6 and 7, CD4 + cells were seen in greater numbers than CD8 + cells in both the dermis and epidermis (fig 2) . In cases 1,3,4,8 and 9 comparative analysis of CD8 + cells with CD3 + cells revealed only scanty CD8 + cells, despite large numbers of cells expressing the pan T cell marker (fig 3) , suggesting that most infiltrating T cells were of the CD4 + T helper/inducer subset. Discussion All nine patients studied had a skin rash; five patients also had liver dysfunction, two of whom also had lower gastointestinal GvHD. Six of the nine patients died, including all five patients with liver dysfunction. The tendency for TA-GvHD to have a fulminant course, which is clearly illustrated by this study, Figure 3 Formalin fixed skin biopsy specimen from case 3 with TA-GvHD, showingflorid CD3 + infiltration (above) (nickelmodified DAB with postdevelopment enhancement in TRIS-cobalt, compared with scanty CD8 + cells (below) (standard DAB development); e = epidernis, d = dermis.
In the present study we investigated aberrant keratinocyte expression of HIA-DR in nine patients with transfusion associated GvHD. All nine patients showed aberrant eexpression of HLA-DR by epidermal keratinocytes in biopsy specimens from lesional tissue, indicating that the immunopathological profile of TA-GvHD is similar to that of BMT related GvHD, and that epidermal HLA-DR expression is a useful immunohistochemical marker of both conditions. Furthermore, all four patients with diffuse epidermal expression of HIA-DR died; three of the five d patients in whom HLA-DR expression was less strongly positive and more focal survived. This suggests that the extent of epidermal HLA-DR positivity may be an indicator of disease severity in TA-GvHD and so may be of prognostic as well as diagnostic importance.
In our previous study11 only one out of 12 autologous recipients showed focal positive epidermal expression of HLA-DR after BMT, having been DR positive before BMT. We have reported elsewhere that many of the autologous BMT recipients analysed in this earlier study had In contrast to these results, we also analysed a skin biopsy specimen from a 7 year old girl with Burkitt's lymphoma who developed a diffuse erythematous skin rash after high dose methotrexate, which was initially attributed to TA-GvHD. Histological results proved equivocal, with epidermal changes more suggestive of a drug induced lesion. The rash resolved spontaneously, and was eventually attributed to drug toxicity. Immunohistochemical analysis of the biopsy specimen from this patient showed no epidermal expression of HLA-DR and no T cell infiltration (unpublished data).
In conclusion, the immunopathological profile of TA-GvHD is similar to that of BMT related GvHD, with positive epidermal expression of HIA-DR and dermal infiltration of T lymphocytes being consistent features. The predominant T cells in TA-GvHD are CD4 + T helper/inducer cells. Immunohistochemical analysis of skin biopsy tissue using antibodies recognising HLA-DR and CD4 + is thus a useful investigation in pancytopenic patients presenting with unexplained rashes. By facilitating early diagnosis and treatment, we suggest that immunohistochemical analysis has an important role in the successful management of TA-GvHD that complicates intensive chemotherapy for malignant disease.
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